Prognostic significance of tumour infiltrating B lymphocytes in breast ductal carcinoma in situ

Tumour‐infiltrating lymphocytes (TILs) are an important component of the immune response to cancer and have a prognostic value in breast cancer. Although several studies have investigated the role of T lymphocytes in breast cancer, the role of B lymphocytes (TIL‐Bs) in ductal carcinoma in situ (DCIS) remains uncertain. This study aimed to assess the role of TIL‐Bs in DCIS.

[1]  G. Gong,et al.  An Examination of the Local Cellular Immune Response to Examples of Both Ductal Carcinoma In Situ (DCIS) of the Breast and DCIS With Microinvasion, With Emphasis on Tertiary Lymphoid Structures and Tumor Infiltrating Lymphoctytes. , 2016, American journal of clinical pathology.

[2]  L. Esserman,et al.  Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast , 2016, Breast Cancer Research and Treatment.

[3]  Huan Yang,et al.  High Mobility Group Box Protein 1 (HMGB1): The Prototypical Endogenous Danger Molecule , 2015, Molecular medicine.

[4]  H. Lee,et al.  Prognostic Significance of Tumor-Infiltrating Lymphocytes and the Tertiary Lymphoid Structures in HER2-Positive Breast Cancer Treated With Adjuvant Trastuzumab. , 2015, American journal of clinical pathology.

[5]  S. Fineberg,et al.  Correlation of histopathologic features of ductal carcinoma in situ of the breast with the oncotype DX DCIS score , 2015, Modern Pathology.

[6]  T. Mirza,et al.  Differential immune cell densities in ductal carcinoma In-Situ and invasive breast cancer: Possible role of leukocytes in early stages of carcinogenesis , 2015, Pakistan journal of medical sciences.

[7]  T. Nielsen,et al.  The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  D. Rimm,et al.  Multiplexed Quantitative Analysis of CD3, CD8, and CD20 Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer , 2014, Clinical Cancer Research.

[9]  Vamsidhar Velcheti,et al.  In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas , 2014, Clinical Cancer Research.

[10]  John M S Bartlett,et al.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2014, Archives of pathology & laboratory medicine.

[11]  D. Carraro,et al.  Ductal carcinoma in situ of the breast: morphological and molecular features implicated in progression , 2013, Bioscience reports.

[12]  J. Cuzick,et al.  Altered Microenvironment Promotes Progression of Preinvasive Breast Cancer: Myoepithelial Expression of αvβ6 Integrin in DCIS Identifies High-risk Patients and Predicts Recurrence , 2013, Clinical Cancer Research.

[13]  P. Argani,et al.  Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study. , 2013, Human pathology.

[14]  J. Reis-Filho,et al.  Progression from ductal carcinoma in situ to invasive breast cancer: Revisited , 2013, Molecular oncology.

[15]  P. Rochaix,et al.  High Endothelial Venule Blood Vessels for Tumor-Infiltrating Lymphocytes Are Associated with Lymphotoxin β–Producing Dendritic Cells in Human Breast Cancer , 2013, The Journal of Immunology.

[16]  Benjamin Haibe-Kains,et al.  CD4⁺ follicular helper T cell infiltration predicts breast cancer survival. , 2013, The Journal of clinical investigation.

[17]  Bonnie F. Sloane,et al.  Next-generation sequencing: a powerful tool for the discovery of molecular markers in breast ductal carcinoma in situ , 2013, Expert review of molecular diagnostics.

[18]  M. Shurin,et al.  Clinical evaluation of systemic and local immune responses in cancer: time for integration , 2013, Cancer Immunology, Immunotherapy.

[19]  B. Nelson,et al.  Tumor-infiltrating B cells and T cells , 2012, Oncoimmunology.

[20]  David Haussler,et al.  Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling , 2011, Proceedings of the National Academy of Sciences.

[21]  Laura J. Esserman,et al.  Leukocyte composition of human breast cancer , 2011, Proceedings of the National Academy of Sciences.

[22]  P. V. van Diest,et al.  Molecular differences between ductal carcinoma in situ and adjacent invasive breast carcinoma: a multiplex ligation-dependent probe amplification study , 2011, Cellular Oncology.

[23]  Laurence Zitvogel,et al.  Immune parameters affecting the efficacy of chemotherapeutic regimens , 2011, Nature Reviews Clinical Oncology.

[24]  Andrew R. Green,et al.  MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroups , 2011, Breast Cancer Research and Treatment.

[25]  Keda Yu,et al.  Different Distribution of Breast Cancer Subtypes in Breast Ductal Carcinoma in situ (DCIS), DCIS with Microinvasion, and DCIS with Invasion Component , 2011, Annals of Surgical Oncology.

[26]  P. Tsimbouri,et al.  Lymphocyte deficiency limits Epstein-Barr virus latent membrane protein 1 induced chronic inflammation and carcinogenic pathology in vivo , 2011, Molecular Cancer.

[27]  Jungsil Ro,et al.  The invasive lobular carcinoma as a prototype luminal A breast cancer: A retrospective cohort study , 2010, BMC Cancer.

[28]  B. Nelson,et al.  CD20+ B Cells: The Other Tumor-Infiltrating Lymphocytes , 2010, The Journal of Immunology.

[29]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Archives of pathology & laboratory medicine.

[30]  Carsten Denkert,et al.  Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  J. Blay,et al.  Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. , 2009, Cancer research.

[32]  Xiao-Jun Ma,et al.  Gene expression profiling of the tumor microenvironment during breast cancer progression , 2009, Breast Cancer Research.

[33]  Thomas F. Tedder,et al.  Maintenance of Long-Lived Plasma Cells and Serological Memory Despite Mature and Memory B Cell Depletion during CD20 Immunotherapy in Mice1 , 2008, The Journal of Immunology.

[34]  F. Ronchese,et al.  Resting B Cells Suppress Tumor Immunity via an MHC Class-II Dependent Mechanism , 2007, Journal of immunotherapy.

[35]  Stephen B Fox,et al.  Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  M. Hussein,et al.  Analysis of the mononuclear inflammatory cell infiltrate in the normal breast, benign proliferative breast disease, in situ and infiltrating ductal breast carcinomas: preliminary observations , 2006, Journal of Clinical Pathology.

[37]  G. Sakamoto,et al.  Immunophenotype of lymphocytic infiltration in medullary carcinoma of the breast , 2004, Virchows Archiv.

[38]  E. Hersh,et al.  Naturally occurring B-cell responses to breast cancer , 2003, Cancer Immunology, Immunotherapy.

[39]  M. Barbareschi,et al.  High syndecan‐1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis , 2003, Cancer.

[40]  H. Ditzel,et al.  Translocation of an Intracellular Antigen to the Surface of Medullary Breast Cancer Cells Early in Apoptosis Allows for an Antigen-Driven Antibody Response Elicited by Tumor-Infiltrating B Cells1 , 2002, The Journal of Immunology.

[41]  H. Ditzel,et al.  The tumor-infiltrating B cell response in medullary breast cancer is oligoclonal and directed against the autoantigen actin exposed on the surface of apoptotic cancer cells , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[42]  Alan C. Rapraeger,et al.  Syndecan-Regulated Receptor Signaling , 2000, The Journal of cell biology.

[43]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. , 1999, Critical reviews in oncology/hematology.

[44]  A. Barsoum,et al.  Human breast carcinoma patients develop clonable oncofetal antigen-specific effector and regulatory T lymphocytes. , 1999, Journal of immunology.

[45]  G. Nicolardi,et al.  Computerised counting of tumour infiltrating lymphocytes in 90 breast cancer specimens. , 1999, Cancer letters.

[46]  P. Zimmermann,et al.  The syndecans, tuners of transmembrane signaling , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[47]  A. Pinto,et al.  Characterization of anti‐CD138 monoclonal antibodies as tools for investigating the molecular polymorphism of syndecan‐1 in human lymphoma cells , 1999, British journal of haematology.

[48]  Masato Kato,et al.  Physiological degradation converts the soluble syndecan-1 ectodomain from an inhibitor to a potent activator of FGF-2 , 1998, Nature Medicine.

[49]  L. Ginaldi,et al.  Levels of expression of CD19 and CD20 in chronic B cell leukaemias. , 1998, Journal of clinical pathology.

[50]  P. V. van Diest,et al.  Expression of growth factors, growth‐inhibiting factors, and their receptors in invasive breast cancer. II: Correlations with proliferation and angiogenesis , 1998, The Journal of pathology.

[51]  L. Happerfield,et al.  Angiogenesis and inflammation in ductal carcinoma in situ of the breast , 1997, The Journal of pathology.

[52]  B. Klein,et al.  A plasmocyte selective monoclonal antibody (B‐B4) recognizes syndecan‐1 , 1996, British journal of haematology.

[53]  Wim Timens,et al.  Leucocyte typing V. White cell differentiation antigens , 1995 .

[54]  T. Tedder,et al.  CD20: a regulator of cell-cycle progression of B lymphocytes. , 1994, Immunology today.

[55]  S. Pinder,et al.  Pathological prognostic factors in breast cancer. III. Vascular invasion: relationship with recurrence and survival in a large study with long‐term follow‐up , 1994, Histopathology.

[56]  J. Raus,et al.  Phenotypic analysis of tumor-infiltrating lymphocytes from human breast cancer. , 1992, Anticancer research.

[57]  J. Spring,et al.  Biology of the syndecans: a family of transmembrane heparan sulfate proteoglycans. , 1992, Annual review of cell biology.